BioCentury
ARTICLE | Emerging Company Profile

Abac’s precision platform

How Abac’s pathogen-specific approach could reduce emergence of antibiotic resistance

May 10, 2018 9:31 PM UTC

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics.

The company’s PasNas platform uses phenotypic and in vitro assays to screen chemical libraries and identify pathogen-specific antibiotics for multidrug resistant microbes. According to CSO Domingo Gargallo-Viola, PasNas can identify candidates for any infectious microbial species, regardless of mechanism of action or molecular target, which are determined later in development...